RxDoctor Payments Data

Thomas Hart, NP

Nurse Practitioner · Tallahassee, FLNPI 1417474180

Payments from drug & device makers

$2,110in general payments, 2019–2025

Across 69 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$973
  • AbbVie$141
  • Novo Nordisk$127
  • Lilly USA, LLC$122
  • UCB, Inc.$111
  • Intuitive Surgical$109
  • plus $527 from 16 others

What the payments were for

  • Travel & lodging$64030%
  • Food & beverage$1,47070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,110 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$22,969
Medicare patients
85
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide364$467,742
OzempicSemaglutide250$307,060
Invega SustennaPaliperidone Palmitate12$45,132
TrulicityDulaglutide33$38,278
WegovySemaglutide23$31,018
JardianceEmpagliflozin102$16,210
EliquisApixaban70$11,494
JanuviaSitagliptin Phosphate25$9,063
JanumetSitagliptin Phos/Metformin Hcl50$7,696
Methenamine Hippurate166$4,458
FarxigaDapagliflozin Propanediol23$3,488
Meropenem-0.9% NaclMeropenem-0.9% Sodium Chloride15$2,806
Tresiba Flextouch U-100Insulin Degludec11$2,101
Carbamazepine49$1,860
Levothyroxine Sodium325$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$122$506,020397 claims
Novo NordiskOzempic, Wegovy$127$338,079273 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$1,749325 claims
Almatica Pharma LLCSertraline Hcl$31$57592 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →